A recent pilot study [15] demonstrated the potential utility of PSMA PET in selecting papillary thyroid cancer patients for possible PSMA radioligand therapy, but this has not been evaluated in other thyroid cancer subtypes. This evidence concerns the gene FOLH1 and thyroid gland papillary carcinoma.